Will Lewis.

Will Lewis runs Insmed, a biopharmaceutical company focused on serious and rare diseases.

Insmed's approved product Arikayce treats refractory Mycobacterium avium complex lung disease, and the pipeline includes brensocatib - a potentially first-in-class treatment for non-cystic fibrosis bronchiectasis that could become a major commercial product. Under Lewis's leadership, Insmed has grown from a small clinical-stage company into a commercial-stage biopharmaceutical business with meaningful revenue and a pipeline targeting several large rare disease indications. He was named a 2025 EY Entrepreneur of the Year National Health Award finalist. Running a mid-cap biopharmaceutical company focused specifically on rare diseases requires navigating complex regulatory pathways, specialty commercialization infrastructure, and significant capital discipline across multiple cycles - the kind of patient, technical work that does not produce dramatic headlines but takes real operating skill to execute. Lewis has done it through a period when many similar-stage companies have struggled to transition from clinical development to sustainable commercial businesses.